Chargement en cours...
C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has transformed the natural history of relapsed and refractory B-cell acute lymphoblastic leukemia and aggressive B-cell non-Hodgkin lymphoma. Based on these results, CD19 CAR T cells have since been tested in largely incurable lymphomas,...
Enregistré dans:
| Publié dans: | Blood Adv |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Hematology
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7686908/ https://ncbi.nlm.nih.gov/pubmed/33232481 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003391 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|